Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

10145	Companies
208321	Keywords
138377	Articles
110383	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

PRESS RELEASE

published on 09/15/2025 at 16:45, 6 months 16 days ago

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Protagonist Therapeutics to present Phase 2b ANTHEM-UC study data on targeted oral peptide icotrokinra at UEGW Week 2025 in Berlin. Company focuses on advanced therapies in ulcerative colitis

Ulcerative Colitis Protagonist Therapeutics Icotrokinra Phase 2b ANTHEM-UC Study UEGW Week 2025
BRIEF

published on 09/11/2025 at 14:05, 6 months 20 days ago

Un acteur majeur sollicite l'approbation de l'EMA pour l'icotrokinra dans le traitement du psoriasis

Essais Cliniques Icotrokinra Psoriasis En Plaques Efficacité Du Traitement Demande D'admission À L'EMA
BRIEF

published on 09/11/2025 at 14:05, 6 months 20 days ago

Protagonist Seeks EMA Approval for Icotrokinra in Psoriasis

Clinical Trials Plaque Psoriasis Icotrokinra Treatment Efficacy EMA Application
PRESS RELEASE

published on 09/11/2025 at 14:00, 6 months 20 days ago

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Protagonist Therapeutics submits application to EMA for first approval of icotrokinra, an investigational targeted oral peptide blocking IL-23 receptor in plaque psoriasis treatment

Protagonist Therapeutics Plaque Psoriasis Treatment IL-23 Receptor Icoktrokinra EMA Submission
BRIEF

published on 08/26/2025 at 22:10, 7 months 6 days ago

Protagonist Therapeutics Engages in Key Investment Conferences

Clinical Trials Protagonist Therapeutics Investment Conferences Biopharmaceutical Development Icotrokinra And Rusfertide
BRIEF

published on 08/26/2025 at 22:10, 7 months 6 days ago

Protagonist Therapeutics participe à des conférences d'investissement clés

Essais Cliniques Thérapeutique Protagoniste Conférences D'investissement Développement Biopharmaceutique Icotrokinra Et Rusfertide
PRESS RELEASE

published on 08/26/2025 at 22:05, 7 months 6 days ago

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
Protagonist Therapeutics announced CEO's participation in investment bank conferences in September. Company's advanced Phase 3 clinical development and future plans highlighted

Protagonist Therapeutics Phase 3 Clinical Development NDA Submission Investment Bank Conferences Drug Discovery Programs
BRIEF

published on 08/25/2025 at 13:05, 7 months 7 days ago

Le Rusfertide de Protagonist Therapeutics reçoit la désignation de thérapie révolutionnaire de la FDA

Rusfertide Thérapeutique Protagoniste Polyglobulie Vraie Thérapie Révolutionnaire Phase 3 VÉRIFIER
BRIEF

published on 08/25/2025 at 13:05, 7 months 7 days ago

Protagonist Therapeutics' Rusfertide Receives FDA Breakthrough Therapy Designation

Protagonist Therapeutics Rusfertide Polycythemia Vera Breakthrough Therapy Phase 3 VERIFY
PRESS RELEASE

published on 08/25/2025 at 13:00, 7 months 7 days ago

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
Protagonist Therapeutics' rusfertide granted Breakthrough Therapy Designation by the FDA for polycythemia vera, complementing Orphan Drug and Fast Track designations. NDA filing on track for Q4

FDA Protagonist Therapeutics Rusfertide Breakthrough Therapy Designation NDA Filing

Accesswire

Published on 04/02/2026 at 04:00, just now

MedMira Reports Second Quarter Results FY2025
Published on 04/02/2026 at 00:55, 3 hours 5 minutes ago

Silver Spruce Resources Inc. Announces Close of $739,250 First Tranche of Non-Brokered Private Placement and Extension
Published on 04/02/2026 at 00:00, 4 hours ago

Northern Dynasty Makes Annual Filings
Published on 04/02/2026 at 00:00, 4 hours ago

Redwood AI Launches Collaborative Research Project with UBC's Brent Page Lab Focused on Alzheimer's Drug Discovery
Published on 04/01/2026 at 23:15, 4 hours 45 minutes ago

Golden Minerals Reports Full Year 2025 Results

View all ACCESSWIRE

EQS Group

Published on 04/02/2026 at 00:52, 3 hours 8 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3H
Published on 04/01/2026 at 22:30, 5 hours 30 minutes ago

EQS-Adhoc: Deutsche Rohstoff AG:
Published on 04/01/2026 at 22:23, 5 hours 37 minutes ago

EQS-Adhoc: Deutsche Börse AG: US court grants decision to plaintiffs’ group seeking turnover of assets attributed to Bank Markazi and held by Clearstream
Published on 04/01/2026 at 22:05, 5 hours 55 minutes ago

Abivax publie ses rapports financiers auprès des autorités françaises et américaines de régulation des marchés financiers
Published on 04/01/2026 at 22:05, 5 hours 55 minutes ago

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Les Echos

Published on 04/01/2026 at 19:16, 8 hours 44 minutes ago

Mars 2026 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
Published on 04/01/2026 at 18:15, 9 hours 45 minutes ago

Accor signs a memorandum of understanding on the sale of its stake in Essendi
Published on 04/01/2026 at 18:15, 9 hours 45 minutes ago

Accor a signé un protocole d’accord pour la cession de sa participation dans Essendi
Published on 04/01/2026 at 18:02, 9 hours 58 minutes ago

CP MOULINVEST : TRANSFERT DU CONTRAT DE LIQUIDITE AUPRES DE TPICAP
Published on 04/01/2026 at 18:00, 10 hours ago

Closing of acquisition of Chaplin's World operating company

View all LES ECHOS COMFI WIRE